ReviewBritish journal of haematology2017
Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype.
Review in British journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 113 citations in OpenAlex.
- Prevalence of Serologic Weak D Phenotype in Iranian Blood Donors: A Nationwide Retrospective Cross-Sectional Study.Health science reports · 2026Article
- Whole genome sequencing of 1427 Mexican individuals from the oriGen cohort.Nature communications · 2026Article
- On the Differentiation of Auto- and Allo-Anti-D: The Significance of DAT and Autocontrol.Iranian journal of pathology · 2026Article
- Genetic diversity of the RHD gene in blood donors from the Brazilian Central-West.Hematology, transfusion and cell therapy · 2026Article
- Geographic boundary for the Asian-type DEL in south Asia.iScience · 2026Article
- The Complexity of Weak Rhesus Positivity in Pregnancy: Challenges and Management.Clinical practice and cases in emergency medicine · 2026Article
- Association between ABO/Rh blood groups and transfusion-transmitted infections among Turkish blood donors: a comprehensive demographic analysis (2015-2021).BMC infectious diseases · 2026Article
- Weak D phenotype in transfusion medicine and obstetrics: Challenges and opportunities.World journal of experimental medicine · 2025Review
- IntegratingMedicina (Kaunas, Lithuania) · 2025Article
- Article
- Article
- Single-exon fetal RHD genotyping: a 31-month follow up in the obstetric population of Western Sweden.Blood transfusion = Trasfusione del sangue · 2024Article
- Evaluation of the LightCyclerBiomedicines · 2024Article
- Simultaneous high throughput genotyping of 36 blood group systems using NGS based on probe capture technology.Heliyon · 2024Article
- Guide to Rho(D) Immune Globulin in Women With Molecularly Defined Asian-type DEL (c.1227G>A).Annals of laboratory medicine · 2024Review
- Article
- Asian-type DEL (RHD*DEL1) with an allo-anti-D: A paradoxical observation in a healthy multiparous woman.Transfusion · 2023Article
- Variant RHD alleles and Rh immunization in patients with sickle cell disease.British journal of haematology · 2023Article
- Genotype analysis to clarify RhD variants in discrepant samples of Chilean population.Frontiers in immunology · 2023Article
- Transfusion support for a woman withImmunohematology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Approximately 0·2-1% of routine RhD blood typings result in a "serological weak D phenotype." For more than 50 years, serological weak D phenotypes have been managed by policies to protect RhD-negative women of child-bearing potential from exposure to weak D antigens. Typically, blood donors with a serological weak D phenotype have been managed as RhD-positive, in contrast to transfusion recipients and pregnant women, who have been managed as RhD-negative. Most serological weak D phenotypes in Caucasians express molecularly defined weak D types 1, 2 or 3 and can be managed safely as RhD-positive, eliminating unnecessary injections of Rh immune globulin and conserving limited supplies of RhD-negative RBCs. If laboratories in the UK, Ireland and other European countries validated the use of potent anti-D reagents to result in weak D types 1, 2 and 3 typing initially as RhD-positive, such laboratory results would not require further testing. When serological weak D phenotypes are detected, laboratories should complete RhD testing by determining RHD genotypes (internally or by referral). Individuals with a serological weak D phenotype should be managed as RhD-positive or RhD-negative, according to their RHD genotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.